Rubinson Douglas A, Wolpin Brian M
Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA; Harvard Medical School, 25 Shattuck St, Boston, MA 02115, USA.
Harvard Medical School, 25 Shattuck St, Boston, MA 02115, USA; Pancreas and Biliary Tumor Center, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.
Hematol Oncol Clin North Am. 2015 Aug;29(4):761-76. doi: 10.1016/j.hoc.2015.04.012. Epub 2015 Jun 9.
Since the US Food and Drug Administration's approval of gemcitabine in 1996, numerous randomized trials have investigated treatment programs to further improve the quality of life and survival of patients with advanced pancreatic cancer. After little progress over the ensuing 15 years, 2 combination treatment programs recently conferred improved survival compared with gemcitabine monotherapy in patients with metastatic pancreatic cancer: FOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan, oxaliplatin) and gemcitabine plus nab-paclitaxel. Importantly, our understanding of the biology of pancreatic cancer continues to grow. This improved biologic understanding holds great promise for integrating new targeted and immune-modifying therapies into current treatment programs.
自1996年美国食品药品监督管理局批准吉西他滨以来，众多随机试验对治疗方案进行了研究，以进一步提高晚期胰腺癌患者的生活质量和生存率。在随后的15年里进展甚微，最近有两种联合治疗方案在转移性胰腺癌患者中显示出比吉西他滨单药治疗更高的生存率：FOLFIRINOX（亚叶酸、5-氟尿嘧啶、伊立替康、奥沙利铂）和吉西他滨联合白蛋白结合型紫杉醇。重要的是，我们对胰腺癌生物学的理解不断加深。这种对生物学认识的提高为将新的靶向治疗和免疫调节治疗纳入当前治疗方案带来了巨大希望。
